SCHEMBL24155508

SCHEMBL24155508

FC(F)Oc1cccc(Oc2ncc(-c3ccc4nccn4c3)cn2)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.44
BTK Q06187 4/20 0.44
DYRK1A Q13627 2/20 0.42
GRM2 Q14416 1/20 0.41
JAK2 O60674 1/20 0.41
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
RET P07949 2/20 0.37
TGFBR1 P36897 5/20 0.37
PIK3CA P42336 2/20 0.36
RXRA P19793 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
KCNH2 Q12809 1/20 0.36
AKT1 P31749 1/20 0.36
MTOR P42345 1/20 0.36
TGFBR2 P37173 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24155653 0.87 NAMPT (0.43) EGFRBTKDYRK1AMEN1HTT
SCHEMBL24155858 0.86 DYRK1A (0.46) EGFRBTKDYRK1AJAK2MEN1
SCHEMBL24155658 0.85 DYRK1A (0.45) EGFRBTKDYRK1AJAK2MEN1
SCHEMBL31674515 0.83 MEN1 (0.49) EGFRBTKDYRK1AJAK2MEN1
SCHEMBL24155510 0.83 MEN1 (0.58) DYRK1AJAK2MEN1HTTKMT2A
SCHEMBL24155659 0.83 MEN1 (0.49) EGFRBTKDYRK1AJAK2MEN1
SCHEMBL24155873 0.82 RET (0.50) EGFRBTKDYRK1AMEN1HTT
SCHEMBL21995639 0.82 MEN1 (0.52) DYRK1AJAK2MEN1KMT2ARET
SCHEMBL24155663 0.79 TGFBR1 (0.50) DYRK1AJAK2MEN1HTTKMT2A
SCHEMBL24155684 0.79 DYRK1A (0.51) DYRK1AJAK2MEN1KMT2ARET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B EGFR 4648/4885BTK 3398/4885DYRK1A 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.